PLUG Dementia Trial and MRI PLUG Dementia Sub-Study

Terminated

• Conditions: Atrial Fibrillation; Dementia; Cognitive Decline
• Interventions: Other: Questionnaire; Diagnostic Test: Magnetic Resonance Imaging

• Registration Number: NCT03091855
• Lead Sponsor: Intermountain Health Care, Inc.

Brief Summary

PLUG Dementia Trial:

Patients will be screened at Intermountain Medical Center and at Intermountain affiliated anticoagulation clinics in the Salt Lake City region. Patients with atrial fibrillation that undergo a standard of care, clinically approved, left atrial appendage closure will be considered for study. All patients will be followed for 24 months, and will be assessed at the 3-, 6-, 12-, 18- and 24-months post-left atrial appendage closure as well as other visits deemed necessary for clinical care. All subjects will undergo protocol-specified laboratory tests and will complete 6 standard, validated questionnaires at each follow-up visit, except at the 3-month visit when only one questionnaire will be administered. A subset of patients (n=20), will receive a cranial MRI at baseline and 24-month visit.

MRI PLUG Dementia Sub-Study:

In addition to the above, 20 of the 60 subjects who are selected for participation in this sub-study will receive a cranial MRI at baseline and at the 2-year (24 months) follow-up visit.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-03-15
• Study First Submitted QC: 2017-03-24
• Study First Posted: 2017-03-27
• Study Start: 2017-04-03
• Primary Completion: 2021-01-08
• Study Completion: 2021-01-08
• Status Verified: 2021-04
• Last Update Submitted: 2021-04-01
• Last Update Posted: 2021-04-05

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

1. Male or female >65 years of age
2. Atrial fibrillation documented by electrocardiogram, ambulatory event monitor, or telemetry within 6 months of enrollment
3. Moderate risk of thromboembolism based upon a CHADS2 score or CHADS2 Vasc score of ≥2.
4. Recipient of a left atrial appendage closure device within 3 months of enrollment (within 6 months, for patients considered for the MRI PLUG Dementia Sub-Study)
5. Have the ability to complete a mini-mental status evaluation
6. Have the ability to independently comprehend and complete a quality of life and dementia questionnaires.
7. Ability to provide informed consent for study participation
8. Willing and able to comply with the prescribed follow-up tests and schedule of evaluations.

Exclusion Criteria

1. Have a history of any form of dementia
2. Have a life expectancy less than 24 months
3. Are unable to comply with the follow-up schedule
4. An upper age limit not to be used if participation inclusion criteria are met.
5. Participation in any other clinical trials involving an investigational or marketed drug within 30 days prior to entry in this study;
6. Other conditions that in the opinion of the Principal Investigator may increase risk to the subject and/or compromise the quality of the clinical trial
7. The Principal Investigator(s) determine(s) that the subject is not eligible for participation in this research study.

In addition to the above exclusion criteria, patients considered for the MRI PLUG Dementia Sub-Study will be excluded if the patient -

1. Does not receive a left atrial appendage closure device
2. Has contraindication towards the MRI scan (presence of a nonconditional cardiac implantable device, a history of metallic implants, shrapnel, neurosurgical clip placement)
3. Has conditional cardiac MRI cardiac implantable device, joint replacements, coronary stents, ASD/PFO closure devices, sternal wires or most prosthetic heart valves
4. Has severe renal dysfunction, defined as a creatinine clearance <15 mL/min (documented within the last 3 months)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
PLUG Dementia Trial	Questionnaire	Patients with atrial fibrillation that undergo a standard of care, clinically approved, left atrial appendage closure will be considered for study. All patients will be followed for 24 months, and will be assessed at the 3-, 6-, 12-, 18- and 24-months post-left atrial appendage closure as well as other visits deemed necessary for clinical care. All subjects will undergo protocol-specified laboratory tests and will complete 6 standard, validated questionnaires at each follow-up visit, except at the 3-month visit when only one questionnaire will be administered.
MRI PLUG Dementia Sub-Study	Magnetic Resonance Imaging	20 of the 60 subjects who are selected for participation in this sub-study will receive a cranial MRI at baseline and at the 2-year (24 months) follow-up visit.

Primary Outcome Measures

Name	Time	Method
Dementia Incidence	24 months	Incident dementia determined by a formal diagnosis by a neurologist.
Incidence of baseline micro- and macro-cerebral ischemic events (Sub-study Participants)	24 months	assess the incidence of baseline micro- and macro-cerebral ischemic events (both bleeds and clots) at the time of left atrial appendage closure and compare this with a serial study.
Change in cognitive decline	24 months	Moderate cognitive decline defined as a 30% decrease in Alzheimer's Disease Assessment Scale score or those with a score \<50% or a 30% change on the Disability Assessment for Dementia.

Secondary Outcome Measures

Name	Time	Method
Changes in cranial MRI	24 months	Incidence of bleeding and/or clots in the brain.

Trial Locations

Locations (1)

Intermountain Heart Institute; 🇺🇸 Murray, Utah, United States